|
Match
|
Document |
Document Title |
|
|
6395268 |
Lymphotactin uses
This invention relates to the use of lymphotactin or lymphotactin antagonists for administration to an animal. The administration of these therapeutic entities will attract certain cell types, or...
|
|
|
6391296 |
Method of stabilizing useful protein and useful protein compositions
A method of stabilizing a useful protein by mixing a useful protein and an aqueous solution of a compound having the basic structure of arabic acid, and a stabilizied useful protein compositon...
|
|
|
6392018 |
EGF MOTIF protein obtained from a cDNA library of fetal liver-spleen
The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins....
|
|
|
6387391 |
Bioresorbable polymeric clayey and sticky substance
This invention provides a claycy and sticky substance as a new biomaterial that cannot be found in the current medical field, which is bioresorbable, shows tackiness, plasticity and shape holding...
|
|
|
6387365 |
Combination therapy for chronic hepatitis C infection
There is disclosed a method for treating chronic hepatitis C infection in patients in need of such treating comprising administering an amount of alpha interferon in association with an amount of...
|
|
|
6383480 |
Composition comprising midkine or pleiotrophin protein and method of increasing hematopoietic cells
The present invention provides novel use of the MK family that is used alone as an agent for proliferating hematopoietic stem cells and hematopoietic precursor cells. The invention also provides an...
|
|
|
6383782 |
MCP-1 analogs
Novel Analogues of Monocyte Chemoattractant Protein-1 (MCP-1) have substitution of an alanine, glycine or threonine for the natural valine in position 9 of MCP-1 (9-76).
|
|
|
6383479 |
Neutrophil-activating factor
Biologically active, pure neutrophil-activating factor (NAF) isolated from human monocytes or after expression of a synthetic NAF gene in E.coli and having the following amino acid sequence ...
|
|
|
6383494 |
Methods and composition for eliciting an immune response with gp96-peptide complexes
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases....
|
|
|
6379661 |
Pharmaceutical compositions comprising pluripotent granulocyte colony-stimulating factor
Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte...
|
|
|
6379662 |
Co-administration of interleukin-3 mutant polypeptides with CSF's for multi-lineage hematopoietic cell production
The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with a other colony stimulating factors (CSF), cytokines, lymphokines,...
|
|
|
6380362 |
Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
Novel polynucleotides including partial and extended sequences, and open reading frames, are provided, together with probes and primers, DNA constructs comprising the polynucleotides, biological...
|
|
|
6375946 |
Enhanced activation of natural killer cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
A method for providing activated natural killer (NK) cells comprising the steps of administering to a population of cells which includes lymphocytes and monocytes, an effective amount of an NK cell...
|
|
|
6376541 |
Upregulation of endogenous prostaglandins to lower intraocular pressure
A method of lowering intraocular pressure (IOP) employs an upregulating agent that induces increased prostaglandin synthesis in the eye. The method of treatment entails administering to the eye of...
|
|
|
6372456 |
Polynucleotides encoding chemokine α-6
The present invention relates to a novel CK(α-6 protein which is a member of the alpha chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CKα-6...
|
|
|
6368854 |
Hypoxia mediated neurogenesis
Methods are described for the production of neurons or neuronal progenitor cells. Multipotent neural stem cells are proliferated in the presence of growth factors and erythropoietin which induces...
|
|
|
6361977 |
Methods of using multivariant IL-3 hematopoiesis fusion protein
The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins,...
|
|
|
6361769 |
Stimulation of host defense mechanisms against viral challenges
A method for stimulating host defense mechanisms in a mammal via administering to the mammal a therapeutically effective amount of an interferon via oromucosal contact. The amount of interferon...
|
|
|
6361976 |
Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with a other colony stimulating factors (CSF), cytokines, lymphokines,...
|
|
|
6358505 |
G-CSF receptor agonists
Disclosed are novel G-CSF receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the multi-functional hematopoietic receptor...
|
|
|
6358697 |
Intracellular pharmaceutical targeting
A method and composition to target compounds into cells such as eosinophils. A ligand for a CCR-3 eosinophil surface receptor is provided under conditions to bind to the receptor and cause...
|
|
|
RE37582 |
Cytokine designated LERK-6
The invention is directed to LERK-6 as a purified and isolated protein, the DNA encoding the LERK-6, host cells transfected with cDNAs encoding LERK-6.
|
|
|
6355237 |
Methods for using the obese gene and its gene product to stimulate hematopoietic development
The present invention relates to methods for using various forms of a novel receptor expressed by hematopoietic and endothelial cells. An additional variant form of this receptor has been detected...
|
|
|
6350856 |
Cytokine suppressive anti-inflammatory drug binding protein
p38beta2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing p38beta2 polypeptides and...
|
|
|
6344192 |
Use of interleukin-15
The invention relates to the use of IL-15 or active variants thereof and/or IL-15 activity enhancing compounds for the manufacture of a pharmaceutical composition for manipulating memory cells of...
|
|
|
6340742 |
Erythropoietin conjugates
Erythropoietin glycoprotein products are disclosed which have the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells. The present...
|
|
|
6331304 |
Macrophage-infecting parasites expressing a granulocyte macrophage colony stimulating factor
Strains of Leishmanda and other macrophage-infecting parasites are provided which express the GM-CSF gene which are useful in treating hosts infected by the parasite and in protecting hosts against...
|
|
|
6331298 |
Wound healing and treatment of fibrotic disorders
A healing composition containing at least one non-fibrotic growth factor in combination with a pharmaceutically acceptable carrier is disclosed. A method of preparation of the composition and...
|
|
|
6328954 |
Use of the IL-4 receptor for the therapy prophylaxis and diagnosis of allergic viral parasitic and bacterial diseases and of fungal infections
The use of the IL-4 receptor for the therapy, prophylaxis and diagnosis of allergic, viral, parasitic and bacterial diseases and of fungal infections. The invention relates to the use of the IL-4...
|
|
|
6322779 |
Recombinant human CSF-1 dimer and compositions thereof
The present invention is directed to an isolated and purified, recombinant, unglycosylated and dimeric CSF-1, the dimeric CSF-1 being biologically active and essentially endotoxin and pyrogen-free,...
|
|
|
6322791 |
Haemopoietic growth factor antagonists and uses therefor
The present invention relates generally to variant recombinant forms of haemopoietic growth factors useful as antagonists to the corresponding native haemopoietic growth factor and their use in...
|
|
|
6322986 |
Method for colorectal cancer prognosis and treatment selection
A method predicting the outcome, and prognosis and indicating treatment for patients afflicted with colorectal cancer by determining whether the number of copies of HER-2/neu gene in cancer cells...
|
|
|
6323321 |
Antibody 97A6
The present invention relates to a monoclonal antibody binding an antigen on the megakaryocytic cell line UT-7. The invention further relates to hybridoma cells producing such an antibody.
|
|
|
6312718 |
Vaccine for B-cell malignancies
A vaccine comprising a liposome preparation including at least one B-cell malignancy-associated antigen, IL-2, alone or in combination with at least one other cytokine, and at least one type of...
|
|
|
6309632 |
Methods for treating HIV-infected patients by administering GM-CSF
Provided are methods for reducing the HIV viral load in HIV-infected patients by administering human GM-CSF. The GM-CSF is administered in conjunction with at least two nucleoside reverse...
|
|
|
6309633 |
Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
The invention provides a drug-oligomer conjugate having the following general formula: ##STR1## wherein D is a therapeutic drug moiety; H and H' are each a hydrophilic moiety, independently...
|
|
|
6303113 |
Process for the production of pharmaceutical preparations containing human protein for infusion or injection purposes
The present invention concerns a process for the production of well-tolerated, preserved injection or infusion solutions containing human protein.
|
|
|
6299871 |
Orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases
Disclosed are an orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases, which comprises an interferon-γ as an effective ingredient and a...
|
|
|
6296844 |
Asialocytokines and treatment of liver disease
The invention features methods for treating liver disease (e.g., viral hepatitis) by administering an asialocytokine (e.g., asialointerferon). The invention also includes methods of targeting a...
|
|
|
6294164 |
Natural killer cell enhancing factor C
A human natural killer cell enhancing factor C and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are...
|
|
|
6290948 |
Method of treating sepsis and ARDS using chamohine beta-10
The invention relates to the method of preventing and treating sepsis and ARDS using chemokine or biologically active fragment thereof, alone or in conjunction with an anti-infective agent.
|
|
|
6291661 |
flt3-L mutants and method of use
A screening method for identifying mutant polypeptides having at least one amino acid difference from a wild type protein involved in a receptor-ligand interaction is disclosed. Also disclosed are...
|
|
|
6284236 |
Cytokine that induces apoptosis
A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with...
|
|
|
6280975 |
IL-6 mutein and DNA encoding thereto
The present invention relates to a new IL-6 mutein, a DNA sequence coding for it, its use in therapy as well as a pharmaceutical composition comprising it. It is a potent IL-6 antagonist and can be...
|
|
|
6274552 |
Composition and method for delivery of biologically-active factors
In accordance with the present invention, a composition and method is provided that allows for the administration of a biologically-active factors to a human or animal. The present invention can be...
|
|
|
6274134 |
Human cell adhesion protein AAMP-1 and uses thereof
The present invention relates, in general, to AAMP-1, and to a peptide derived from the amino-terminal region of AAMP, P189. In particular, the present invention relates to a DNA segment encoding...
|
|
|
6268482 |
Recombinant cytokine designated LERK-6
The invention is directed to LERK-6 as a purified and isolated protein, the DNA encoding the LERK-6, host cells transfected with cDNAs encoding LERK-6.
|
|
|
6264951 |
Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L
There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human...
|
|
|
6261549 |
Human mesenchymal stem cells from peripheral blood
Disclosed is a method for recovering peripheral blood containing a population of cells enhanced in human mesenchymal stem cells from an individual by (i) administering to said individual at least...
|
|
|
6261548 |
Leukaemia inhibitory factor
The present invention provides isolated DNA molecules encoding human and murine LIF and methods of producing LIF by the expression of the isolated DNA and suitable host cells. The invention further...
|